Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable sensor feedback may motivate cancer survivors to exercise more

NCT ID NCT05490641

Knowledge-focused Sponsor: The University of Texas at Arlington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether showing cancer survivors real-time glucose data from a wearable sensor can encourage them to be more physically active. 60 cancer survivors at high risk for type 2 diabetes wore a Fitbit and some also wore a continuous glucose monitor for 4 weeks, receiving personalized text messages. The goal was to see if this approach is feasible and if it increases daily activity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glucose-based biofeedback via continuous glucose monitor and Fitbit activity tracker
What this could lead to
If it works, this could point toward a simple, low-cost way to help cancer survivors become more active and reduce their diabetes risk.
What could go wrong
This is a small, early feasibility study with only 60 participants. It tests whether the approach is practical, not whether it improves health outcomes. Results may not apply to all cancer survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be 18 years or older * have had a diagnosis of cancer * have completed curative-intended treatment for at least 3 months (except hormone therapy or long-term maintenance chemotherapy) * be at high-risk for type 2 diabetes based on the American Diabetes Association Type 2 Diabetes Risk Test * currently insufficiently active * capable of participating in moderate-vigorous intensity unsupervised exercise * have no current diagnosis or history of type 1 or 2 diabetes * able to speak, read, and write in English * have a smartphone with daily internet access Exclusion Criteria: * currently taking oral antidiabetic agents (OADs) * current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin * currently pregnant * on dialysis * have self-reported health issues that limit physical activity * work overnight shifts * unwilling to use the study devices * current participation in other exercise or weight loss-related program or intervention * currently on a low-carb diet * current use of other implanted medical devices such as pacemakers * do not have a smartphone that is compatible with the Fitbit and the LibreLink apps

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Survivorship

Contacts and locations

Locations

  • The University of Texas at Arlington

    Arlington, Texas, 76010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.